)
Nadja Berger
Dr. Nadja Berger leads the chemistry team at CPTx in Planegg near Munich, focusing on the development of conjugates with a particular emphasis on designing targeted lipid nanoparticles (LNPs) for in vivo nucleic acid delivery. She studied chemistry at the University of Cologne and completed her PhD in physical organic chemistry at the Ruhr-University of Bochum, where she investigated the structure and dynamics of cyclic peptides. She gained international research experience at UCC (Ireland) and the Institute for Molecular Bioscience at the University of Queensland (Australia), subsequently working as a postdoc in John D. Lambris’ group at UPenn on peptide drug development. After successfully advancing an innovative technology for peptide and oligonucleotide purification at Belyntic GmbH, she led the R&D team focused on developing a peptide-based vaccine platform. At CPTx, Dr. Berger is now developing and validating novel DNA-tLNPs.